Literature DB >> 7191303

[Anti-inflammatory action of acemetacin (author's transl)].

H Jacobi, P Breier, H D Dell.   

Abstract

The anti-inflammatory efficacy of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetoxy]acetic acid (acemetacin, TV 1322, Rantudil) a new non-steroidal anti-inflammatory agent, is described. The stronger inhibition of inflammation in kaolin-induced edema of the rat paw could experimentally be proved with the new compound in comparison with a series of marketed anti-inflammatory agents. Acemetacin is highly effective following both oral and parenteral administration. Following provocation of inflammation in the rat paw by a series of other different agents acemetacin was more strongly effective than indometacin following oral administration. Clear advantage of acemetacin as against indometacin were shown after influencing Freund's adjuvant induced arthritis. In local inflammation too, for example in the wool pellet test, the development of granulation tissue and exudate was inhibited to the same extent as following application of corticosteroid. Both skin erythema and dye-stuff spreading by inhibition of hyaluronidase were antagonised. From the results obtained with acemetacin in numerous inflammatory models conclusion can be drawn as to the multiple sites of action in the reaction chain of inflammation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7191303

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  The comparative pharmacokinetics of acemetacin in young subjects and elderly patients.

Authors:  R W Jones; A J Collins; L J Notarianni; E Sedman
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

2.  Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin.

Authors:  A E Chávez-Piña; W McKnight; M Dicay; G Castañeda-Hernández; J L Wallace
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.